X @The Wall Street Journal
The Wall Street Journalยท2025-08-17 00:48
Regulatory Concerns - FDA's actions, such as hindering an immunotherapy shot for advanced melanoma and delaying a treatment for a rare disease, raise concerns about its commitment to accelerating life-saving drugs [1] Industry Implications - The industry questions whether FDA Commissioner Marty Makary's claims align with the agency's actual practices regarding drug approval processes [1]